Company Encyclopedia
View More
name
Inventiva SA
IVA.US
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
1.946 T
IVA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking222/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE707.22%A
    • Profit Margin-1833.03%E
    • Gross Margin100.96%A
  • Growth ScoreD
    • Revenue YoY-8.31%D
    • Net Profit YoY-205.39%E
    • Total Assets YoY395.98%A
    • Net Assets YoY87.69%A
  • Cash ScoreD
    • Cash Flow Margin-5.46%D
    • OCF YoY-8.31%D
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreE
    • Gearing Ratio104.98%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Inventiva SA Held Combined Shareholders’ Meeting

    Inventiva SA held its Combined Shareholders’ General Meeting on November 27, 2025. All proposals were approved except for one regarding share capital increases for a company savings plan. This news was generated by Public Technologies using AI and is based on content published by Inventiva SA via GlobeNewswire.

    Reuters·
    US
    IVA
    +0.97%
    Reuters·
    US
    IVA
    +0.97%

    Inventiva SA reports €4.5 million revenue for first nine months of 2025

    Inventiva SA reported €4.5 million in revenue for the first nine months of 2025, with cash and cash equivalents of €97.6 million and €24.7 million in short-term deposits as of September 30, 2025. The revenue included a $10 million milestone payment and $5 million in credit notes from Chia Tai Tianqing Pharmaceutical Group. The company expects its cash position to fund operations until early 2027, with potential extension if additional financing is secured.

    Reuters·
    US
    IVA
    +0.97%
    Reuters·
    US
    IVA
    +0.97%

    Inventiva Announces Trading Resumption Of Its Ordinary Shares On Euronext Paris

    Inventiva SA :INVENTIVA ANNOUNCES TRADING RESUMPTION OF ITS ORDINARY SHARES ON EURONEXT PARIS

    Reuters·
    US
    IVA
    +0.97%
    Reuters·
    US
    IVA
    +0.97%

    Inventiva SA Halts Trading of Ordinary Shares on Euronext Paris

    Inventiva SA has announced a temporary halt in trading of its ordinary shares on Euronext Paris, starting from 9:00 a.m. (CET) on November 13, 2025. This suspension, requested by the company, is linked to a public offering of new American Depositary Shares (ADSs) in the U.S. Trading is expected to resume at approximately 3:30 p.m. (CET) the same day.

    Reuters·
    US
    IVA
    +0.97%
    Reuters·
    US
    IVA
    +0.97%

    Inventiva SA Publishes 2025 Annual Report

    Inventiva SA has published its 2025 Annual Report, detailing business updates and developments since the start of the financial year. Key highlights include results from a proof-of-concept trial for lanifibranor with empagliflozin and the appointment of Andrew Obenshain as the new CEO, effective October 1, 2025. The report also covers the company's financial position and activities for the first half of 2025, as outlined in the half-yearly financial report released on September 29, 2025. The full report is accessible via a provided link.

    Reuters·
    US
    IVA
    +0.97%
    Reuters·
    US
    IVA
    +0.97%
    © 2025 Longbridge｜Disclaimer